Caris Life Sciences [CAI]

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer.

INDUSTRY: HEALTH CARE

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. We have spent the last 17 years developing and building our portfolio of comprehensive, proprietary molecular profiling solutions and generating what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on the more than 6.5 million tests we have run on over 849,000 cases, which have generated measurements of over 38 billion molecular markers. Our current commercial product portfolio is focused on oncology and consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection. more

Market Data & Performance

IPO Details

IPO Date / IPO File Date:05/23/2025

Trade Date:05/24/2025

Price Range ($):$19.00 - $20.00

Offer Shares (mm):23.5M

Underwriters:Underwriters BofA Securities J.P. Morgan Goldman Sachs Citi TD Cowen Evercore ISI Guggenheim Securities BTIG Nomura Securities WR Securities

Deal Size ($mm):$459M

Company Profile

Headquarters:Irving, TX, United States

Founded (Year):2008

Employees at IPO:1

Caris Life Sciences [CAI] Performance

Performance chart data is not available for this company.

Caris Life Sciences [CAI]

Recently Viewed